Drugmaker cuts prices for Ozempic, Wegovy. Here's how much you will pay.

The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications.

Novo Nordisk dropped the price for injectable Wegovy and Ozempic to $349 a month Nov. 17, down from $499 a month, for consumers who purchase the medication directly from the drugmaker, telehealth partners or retail pharmacies. Only the 2 mg dose of Ozempic will remain at $499 a month.

For new customers, Novo Nordisk will sell .25 mg and .5 mg versions of Wegovy and Ozempic for $199 for the first two months. The introductory offer for new self-pay consumers is available through March 31, 2026.

Novo Nordisk's price cuts come after the Trump administration pressured it and rival Eli Lilly to slash the prices of popular weight loss and diabetes medications. In a deal announced Nov. 6, President Donald Trump said that Medicare would cover Novo's Wegovy and Lilly's Zepbound for millions of older adults and that the drugmakers would sell discounted versions of the drugs through the federal government's direct-to-consumer website, TrumpRx, which will launch in 2026.

Novo Nordisk also continues to face competition from compounding pharmacies that sell discounted, knock-off versions of semaglutide, the active ingredient in Wegovy and Ozempic.